UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e000673

2020

Volltextzugriff (PDF)

Analysis of FOXP3 Reveals Multiple Domains Required for Its Function as a Transcriptional Repressor

Journal of Immunology, 2006-09, Vol.177 (5), p.3133-3142

2006

Volltextzugriff (PDF)

Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics

Journal for immunotherapy of cancer, 2024-04, Vol.12 (4), p.e008066

2024

Volltextzugriff (PDF)

Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

Journal for immunotherapy of cancer, 2022-09, Vol.10 (9), p.e004913

2022

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys

The Journal of pharmacology and experimental therapeutics, 2021-11, Vol.379 (2), p.203-210

2021

Volltextzugriff (PDF)

TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function

Nature (London), 2008-05, Vol.453 (7192), p.236-240

2008

Volltextzugriff (PDF)

Characterization of flagellin expression and its role in Listeria monocytogenes infection and immunity

Cellular microbiology, 2004-03, Vol.6 (3), p.235-242

2004

Volltextzugriff (PDF)

1402 A potent, CD8 T cell targeted IL-2 A-Kine with a broad therapeutic window induces antitumor immunity in syngeneic and humanized mouse tumor models

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1560-A1560

2023

Volltextzugriff (PDF)

Insights into transcriptional regulation by FOXP3

Frontiers in bioscience, 2006-05, Vol.11 (1), p.1607

2006

Volltextzugriff (PDF)

Abstract 2202: The combination of a mouse ortholog of ALKS 4230, a selective agonist of the intermediate affinity IL-2 receptor, and the angiogenesis inhibitor lucitanib enhances antitumor activity

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2202-2202

2020

Volltextzugriff (PDF)

Abstract 1848: A novel murine tumor model for assessing the efficacy of neoadjuvant dosing regimens for immunotherapies

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1848-1848

2023

Volltextzugriff (PDF)

Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.659-659

2022

Volltextzugriff (PDF)

Abstract 591: Efficacy of ALKS 4230, a novel immunotherapeutic agent, in murine syngeneic tumor models alone and in combination with immune checkpoint inhibitors

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.591-591

2017

Volltextzugriff (PDF)

Abstract 4281: Determination of the Relative Potency of a Selective Agonist of the Intermediate-Affinity IL-2 Receptor on Lymphocytes from Human, Cynomolgus Monkey and Mouse

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4281-4281

2015

Volltextzugriff (PDF)

Abstract 3158: Ex vivo expansion and activation of human lymphocytes with a selective activator of effector cells

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3158-3158

2015

Volltextzugriff (PDF)

Abstract 2663: Characterization of the pharmacodynamic immune response to a novel immunotherapeutic agent, ALKS 4230, in mice and non-human primates

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2663-2663

2017

Volltextzugriff (PDF)

Correction: HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e000157corr1

2020

Volltextzugriff (PDF)

Abstract 1818: Developing an autologous humanized mouse model to assess responses to novel immunotherapeutics

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1818-1818

2023

Volltextzugriff (PDF)

Abstract 4280: Utilizing a selective agonist of the intermediate-affinity IL-2 receptor with an improved pharmacokinetic profile leads to an enhanced immunostimulatory response With reduced toxicity in mice

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4280-4280

2015

Volltextzugriff (PDF)

Foxp3 is required throughout the life of a regulatory T cell

Science's signal transduction knowledge environment (STKE), 2007-07, Vol.2007 (393), p.pe36

2007

Volltextzugriff (PDF)

TGF-bold beta-induced Foxp3 inhibits T sub(H)17 cell differentiation by antagonizing RORbig gammat function

Nature, 2008-05, Vol.453 (7192), p.236-240

2008

Volltextzugriff (PDF)

TGF-[beta]-induced Foxp3 inhibits T^sub H^17 cell differentiation by antagonizing ROR[gamma]t function

Nature (London), 2008-05, Vol.453 (7192), p.236

2008

Volltextzugriff (PDF)

TGF-β-induced Foxp3 inhibits [T.sub.H]17 cell differentiation by antagonizing RORγt function

Nature (London), 2008-05, Vol.453 (7192), p.236

2008

Volltextzugriff (PDF)

TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function

Nature (London), 2008-05, Vol.453 (7192), p.236

2008

Volltextzugriff (PDF)

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021

JAMA : the journal of the American Medical Association, 2022-01, Vol.327 (4), p.331

2022

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Humans
(11)
Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Animals
(9)
Mice
(6)
Forkhead Transcription Factors - Metabolism
(4)
Immunology
(4)
Immunotherapy
(4)
Lymphocytes
(4)
Cancer
(3)
Cytokines
(3)
Female
(3)
Forkhead Transcription Factors - Genetics
(3)
Male
(3)
Melanoma
(3)
Oncology
(3)
Proteins
(3)
Tumors
(3)
Amino Acid Sequence
(2)
Apoptosis
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

Analysis of FOXP3 Reveals Multiple Domains Required for Its Function as a Transcriptional Repressor

Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics

Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys

TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function

Characterization of flagellin expression and its role in Listeria monocytogenes infection and immunity

1402 A potent, CD8 T cell targeted IL-2 A-Kine with a broad therapeutic window induces antitumor immunity in syngeneic and humanized mouse tumor models

Insights into transcriptional regulation by FOXP3

Abstract 2202: The combination of a mouse ortholog of ALKS 4230, a selective agonist of the intermediate affinity IL-2 receptor, and the angiogenesis inhibitor lucitanib enhances antitumor activity

Abstract 1848: A novel murine tumor model for assessing the efficacy of neoadjuvant dosing regimens for immunotherapies

Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial

Abstract 591: Efficacy of ALKS 4230, a novel immunotherapeutic agent, in murine syngeneic tumor models alone and in combination with immune checkpoint inhibitors

Abstract 4281: Determination of the Relative Potency of a Selective Agonist of the Intermediate-Affinity IL-2 Receptor on Lymphocytes from Human, Cynomolgus Monkey and Mouse

Abstract 3158: Ex vivo expansion and activation of human lymphocytes with a selective activator of effector cells

Abstract 2663: Characterization of the pharmacodynamic immune response to a novel immunotherapeutic agent, ALKS 4230, in mice and non-human primates

Correction: HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma

Abstract 1818: Developing an autologous humanized mouse model to assess responses to novel immunotherapeutics

Abstract 4280: Utilizing a selective agonist of the intermediate-affinity IL-2 receptor with an improved pharmacokinetic profile leads to an enhanced immunostimulatory response With reduced toxicity in mice

Foxp3 is required throughout the life of a regulatory T cell

TGF-bold beta-induced Foxp3 inhibits T sub(H)17 cell differentiation by antagonizing RORbig gammat function

TGF-[beta]-induced Foxp3 inhibits T^sub H^17 cell differentiation by antagonizing ROR[gamma]t function

TGF-β-induced Foxp3 inhibits [T.sub.H]17 cell differentiation by antagonizing RORγt function

TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021

Suchergebnisse filtern